Jazz adds to gains on JZP-6 data

Jazz Pharmaceuticals Inc. (NASDAQ:JAZZ) gained $1.92 (73%) to $4.56 on 27.4 million shares on Monday after issuing a press release detailing final data from a Phase III trial of sodium oxybate ( JZP-6...